JPM vs PFX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
PFX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of improvement across all key financial health metrics. While the stock trades at a discount to book value (P/B 0.53), this is offset by negative net profit margins and a catastrophic Q/Q revenue decline of 149.52%. Despite recent EPS beats, the high PEG ratio (8.40) and a 0/100 technical trend suggest the market is pricing in significant risk. The combination of fundamental decay and bearish price action makes this a high-risk asset.
Compare Another Pair
Related Comparisons
JPM vs PFX: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and PhenixFIN Corporation (PFX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.